# Potential therapeutic target for amyotrophic lateral sclerosis

**URL:** <https://archive.menshealtharchive.com/t/potential-therapeutic-target-for-amyotrophic-lateral-sclerosis/1594>\
**Category:** Research Database\
**Created:** [January 15, 2019, 10:59pm UTC](https://archive.menshealtharchive.com/t/potential-therapeutic-target-for-amyotrophic-lateral-sclerosis/1594 "2019-01-15T22:59:55Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![menshealtharchive](https://yyz1.discourse-cdn.com/flex035/user_avatar/archive.menshealtharchive.com/menshealtharchive/32/587_2.png) [@menshealtharchive](https://archive.menshealtharchive.com/u/menshealtharchive)\
**Post date:** [January 15, 2019, 10:59pm UTC](https://archive.menshealtharchive.com/t/potential-therapeutic-target-for-amyotrophic-lateral-sclerosis/1594/1 "2019-01-15T22:59:55Z")

</div>

> **[Potential therapeutic target for amyotrophic lateral sclerosis: Discovery opens...](https://www.sciencedaily.com/releases/2019/01/190115162311.htm)**
>
> New research has revealed that the protein TDP-43 regulates a gene called Stathmin2 (STMN2). STMN2 shows promise as a therapeutic target and could be the first biomarker ALS, which is extremely difficult to diagnose and treat.

  
New research has revealed that the protein TDP-43 regulates a gene called Stathmin2 (STMN2). STMN2 shows promise as a therapeutic target and could be the first biomarker ALS, which is extremely difficult to diagnose and treat.